Demand and volumepositive · 3 filings
“We may experience increased supply chain challenges and customer demand uncertainty due to rapid changes in global trade policies, which may impact our net sales and profitability.”10-Q · Apr 28, 2026 ↗
NeoGenomics, Inc.
NEO
Market read
NeoGenomics, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 18 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 13 directly disclosed connections are confirming.
Company-1.4% todayVolume comparison unavailable
Market group0 of 18 activeHealthcare Biotech & REITs · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- NEO's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if NEO's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 18 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 13 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- NEO's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods9
Price observations320
Usable filing statements97
Verified relationships11
Evidence supporting the case
- Latest annual revenue changed +10.1% year over year.
- Demand and volume has repeated favorable evidence across 3 filings.
- Supply chain and availability has repeated favorable evidence across 3 filings.
Evidence challenging the case
- Operating margin changed -2.0 percentage points in the latest annual period.
- Net margin changed -2.9 percentage points in the latest annual period.
- Restructuring and cost reductions has repeated adverse evidence across 3 filings.
Questions before a position
- EV/sales is 40% below the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context
Price as of Sep 11, 2026
17.326m+82.3%12m+140.2%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2021-12-31$484.3M+9.0%—+7.3%
2022-12-31$509.7M+5.2%—+3.5%
2023-12-31$591.6M+16.1%—+1.0%
2024-12-31$660.6M+11.6%—+0.9%
2025-12-31$727.3M+10.1%—+1.1%
What management says matters
Persistent and emerging business drivers
Restructuring and cost reductionsnegative · 3 filings
“Restructuring charges decreased $6.7 million in 2025 compared to 2024 due to the completion of the restructuring program in 2024.”10-K · Feb 17, 2026 ↗
Supply chain and availabilitypositive · 3 filings
“We may experience increased supply chain challenges and customer demand uncertainty due to rapid changes in global trade policies, which may impact our net sales and profitability.”10-Q · Apr 28, 2026 ↗
Legal and regulatory exposuremixed · 2 filings
“The planned sale is expected to close within a year, subject to regulatory and other customary closing conditions.”10-Q · Oct 28, 2025 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 3.1× · EV/sales 3.3×. Comparisons use only industry-matched filing peers.
Scenario scaffold
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
17.32-1.4% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for NEO. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for NEO. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind NEO
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
CAICaris Life Sciences, Inc.competitorFeb 17, 2026 ▾
“We also face increased competition from laboratories that are more specialized and focused on particular areas such as liquid biopsies or large tissue based molecular panels such as Guardant Health, Inc., Natera, Inc., Exact Sciences Corp, Caris Life Science,…”
DGXQuest Diagnostics IncorporatedcompetitorFeb 17, 2026 ▾
“Competition Our competitors within the broader genomics profiling space include laboratory companies such as Quest Diagnostics, Laboratory Corporation of America and ARUP.”
Depended on by
CAICaris Life Sciences, Inc.supplierMar 3, 2026 ▾
“Other companies offering testing in the precision oncology industry include Illumina, NeoGenomics, Myriad Genetics, Laboratory Corporation of America, Quest Diagnostics, and BostonGene.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 13 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
NEO is currently a Leader in the organic co-movement group Healthcare Biotech & REITs. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for NEO; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.